Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 101Carcinoma, Non-Small-Cell Lung 88Carcinoma, Renal Cell 54Neoplasm Metastasis 37Squamous Cell Carcinoma of Head and Neck 32Colorectal Neoplasms 32Carcinoma, Hepatocellular 32Lung Neoplasms 31Hodgkin Disease 25Neoplasms 24Urinary Bladder Neoplasms 21Pancreatic Neoplasms 21Carcinoma, Transitional Cell 20Breast Neoplasms 19Stomach Neoplasms 17Brain Neoplasms 17Prostatic Neoplasms 16Small Cell Lung Carcinoma 15Sarcoma 15Multiple Myeloma 14Head and Neck Neoplasms 14Esophageal Neoplasms 14Glioblastoma 11Uterine Cervical Neoplasms 10Rectal Neoplasms 10Neuroendocrine Tumors 10Lymphoma 10Recurrence 9Ovarian Neoplasms 9Nasopharyngeal Carcinoma 9

Interventions

relacorilant 2pembrolizumab 2cabozantinib 2tariquidar 1Specimen Handling 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1Osilodrostat 1Nivolumab 1Magnetic Resonance Spectroscopy 1Gefitinib 1Floxuridine 1Dexamethasone 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adrenal Cortex Neoplasms × Nivolumab × Clear all
NCT02720484 2019-05-01

Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer

Northwestern University

Phase 2 Terminated
10 enrolled 11 charts

Adrenal Cortex Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡